A possible explanation for this discrepancy could be that activating TSHR autoantibodies, characterizing Grave’s disease, fail to activate the TSHR expressed on human melanocytes; otherwise, TH excess produced in Grave’s disease patients could have a dominant protective role against melanoma progression, as explained below (see Figure 1). The gene discussed is TSHR; the disease is Graves disease.